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Postpartumhemorrhage remains a leading cause ofmaternal
morbidity and mortality both in the United States1 and
worldwide.2 Incidence of postpartumhemorrhage is increas-
ing tremendously.3–5 Identification of risk factors for post-
partum hemorrhage is an important component of safety
protocols recommended by the National Partnership for
Maternal Safety.6 Knowledge of maternal risk factors for
hemorrhage improves the clinician’s ability to prepare for
and respond to postpartum hemorrhage.
Thrombocytopenia, defined as a platelet count
< 150,000/mL, is common and complicates approximately
12% of all pregnancies.7,8 Themost common etiology of third
trimester thrombocytopenia is gestational thrombocytope-






Abstract Objective To estimate the association between severity of thrombocytopenia and
postpartum hemorrhage.
Study Design We performed a secondary analysis of a prospective cohort of women
delivering by cesarean or vaginal birth after cesarean conducted by the National
Institute of Child Health and Human Development (NICHD) Maternal–Fetal Medicine
Unit. Women delivering  20 weeks with platelets < 400,000/mL were included.
Thrombocytopenia was defined as predelivery platelets of < 150,000/mL. Primary
outcomes were (1) laboratory evidence of hemorrhage, defined as a decrease in
hemoglobin  4 mg/dL and (2) clinical evidence of hemorrhage, a composite of atony,
transfusion, coagulopathy, hysterectomy, laparotomy, or intensive care unit admis-
sion. Odds ratios were calculated for primary outcomes using thrombocytopenia as a
dichotomous and ordinal variable.
Results A total of 54,597 women were included; 5,611 (10.3%) had antepartum
thrombocytopenia, 1,976 (3.6%) women had laboratory evidence of hemorrhage, and
3,862 (7.1%) had clinical evidence of hemorrhage. Thrombocytopenia was associated
with both laboratory evidence of hemorrhage (adjusted odds ratio [aOR]: 1.60, 95% CI:
1.38–1.86) and clinical evidence of hemorrhage (aOR: 1.68, 95% CI: 1.52–1.83). The
odds of laboratory and clinical evidence of hemorrhage increased incrementally with
severity of thrombocytopenia.
Conclusion Thrombocytopenia is associated with both laboratory and clinical evi-
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preeclampsia and HELLP (hemolysis [H], elevated liver
enzymes [EL], and low platelets [LP]) syndrome, infection,
and immune etiologies. Thrombocytopenia is a known risk
factor for procedural and surgical bleeding complications. In
nonobstetrical populations, spontaneous bleeding occurs
when platelets fall below 10,000 to 20,000/mL.9,10 Platelet
transfusion is recommended prior to major nonneuraxial
surgery for any patient with platelets below 50,000 based on
expert consensus.11,12 While recommendations from the
general surgical literature are applied to the pregnant
population,13 the relationship between platelet count and
hemorrhage risk has not been clearly illustrated in the
obstetric literature. The degree to which mild or severe
thrombocytopenia affects the risk for postpartum hemor-
rhage remains uncertain.
The objective of this studywas to estimate the association
between severity of antepartum thrombocytopenia and risk
of postpartum hemorrhagic morbidity.
Materials and Methods
Study Population
This was a secondary analysis of a prospective, multicenter
cohort of women enrolled in the Eunice Kennedy Shriver
National Institute of Child Health and Human Development
(NICHD) Maternal–Fetal Medicine Unit’s “cesarean regis-
try.” This registry was collected prospectively from 1999 to
2002 at 19 academic hospitals. Women with singleton and
multiple gestations who delivered by primary or repeat
cesarean or by vaginal birth after cesarean section were
included in the registry. Demographic, obstetrical, labor and
delivery, and postpartum characteristics were collected
from medical records by trained researchers in a standar-
dized fashion. The study focused on collecting detailed
information from the delivery hospitalization. The methods
for this study have been previously described.14 A deiden-
tified version of this dataset is now publicly available.
This secondary analysis was reviewed by the Institutional
Review Board (IRB) at the University of North Carolina and
considered exempt.
We included women in this analysis who
delivered  20 weeks of gestation and had a documented
predelivery platelet count < 400,000/mL during the delivery
admission. If more than one platelet count was available, the
platelet count closest to the delivery was used. Mode of
delivery was analyzed as a dichotomous variable, either
cesarean (primary and repeat) or vaginal birth after cesarean
(VBAC) section. Women were considered to have labored if
theywere admitted in active labor orwere induced, regardless
of ultimate mode of delivery. Thrombocytopenia was defined
as a platelet count < 150,000/mL. Women with thrombocy-
topenia were compared with those with a normal platelet
count. Additionally, admissionplatelet countwas examined as
an ordinal variable in increments of 20,000/mL, comparing
womenwith platelet count of 130,000 to 149,999/mL, 110,000
to 129,999/mL, 90,000 to 109,999/mL, 70,000 to 89,999/mL,
50,000 to 69,999/mL, and < 50,000/mL to women with a
normal platelet count (150,000–400,000/mL).
Outcomes
The two primary outcomes of this study were (1) laboratory
evidence of hemorrhage, defined as a decrease in hemoglo-
bin  4 mg/dL from predelivery to postpartum values, and
(2) clinical evidence of hemorrhage, a composite outcome,
including medical treatment of uterine atony, transfusion of
blood products intrapartum or postpartum, coagulopathy,
peripartum hysterectomy, postpartum laparotomy, and
intensive care unit admission. Medical treatment of uterine
atonywas defined as an administration of methylergonovine
or carboprost tromethamine after delivery. Coagulopathy
was defined as decreasing platelets with prolonged partial
thromboplastin time greater than 40 seconds or receipt of
fresh frozen plasma, cryoprecipitate, or platelets.
Statistical Analysis
Maternal demographic and clinical characteristics were com-
pared between women with and without thrombocytopenia
using chi-square and student’s t-test, as appropriate. Two
multivariable logistic regression models were then created,
one with laboratory evidence of hemorrhage morbidity as the
dependent variable and the other with clinical evidence of
hemorrhage as the dependent variable. Initial models
included covariates that were statistically significant in the
bivariate analysis. Because treatment with magnesium has
been associated with an increased risk of postpartum hemor-
rhage,15,16 we elected to include magnesium in the models a
priori. Both thrombocytopenia and magnesium are highly
correlated with preeclampsia; therefore, we did not include
preeclampsia as a confounderdue to colinearity. If information
regarding intrapartum magnesium sulfate treatment was
missing, we presumed women to be unexposed. Stepwise
regression with backward elimination was used to select
an adjusted model. Main effects were retained in the model
if p-values were < 0.20. Variables were considered statisti-
callysignificant in thefinalmodelonly ifp-valueswere < 0.05.
Subgroup analyses were performed to assess for persis-
tence of the relationship between thrombocytopenia and
hemorrhage in the setting of vaginal delivery, cesarean
delivery, and preeclampsia. Statistical significance was de-
fined as p < 0.05. All analyses were performed using STATA
version 14.2 (College Station, TX).
Results
From the original cesarean section registry of 73,257 women,
54,597 women met the inclusion criteria for this analysis
(►Fig. 1).Of these,5,611women(10.3%)hadthrombocytopenia.
Among women with thrombocytopenia, the median platelet
countwas132 (interquartile range [IQR]:115–142); 686women
had a platelet count < 100,000/mL, and 64 had a platelet count
< 50,000. In contrast,womenwithanormalplatelet counthada
median platelet count of 223 (IQR: 191–262).
Women with thrombocytopenia were older; had a lower
BMI; were more likely to be nulliparous, have hypertensive
disorder of pregnancy, receive magnesium; and have a multi-
ple gestation pregnancy (►Table 1). Women with thrombo-
cytopeniawere alsomore likely todeliver preterm(<37weeks
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ofgestation) via cesarean section,with general anesthesia, and
were less likely to have labored compared with women with-
out thrombocytopenia (►Table 1).
A total of 3,862 women (7.1% of all women) experienced
clinical evidence of hemorrhage, and a total of 1,976 women
(3.6% of all women) met criteria for laboratory evidence of
hemorrhage. Also, 754women (1.4% of allwomen)met criteria
for both clinical and laboratory evidence of hemorrhage.
Women with thrombocytopenia were more likely to experi-
ence both laboratory and clinical evidence of hemorrhage;
among women with thrombocytopenia, 11.7% had clinical
evidence of hemorrhage, 8.3% had laboratory evidence of
hemorrhage, and 2.9% had both laboratory and clinical evi-
dence of hemorrhage as compared with 6.5, 3.3, and 1.2%,
respectively, to those without thrombocytopenia (p < 0.001
forall comparisons,►Table 2). The incidenceofboth laboratory
and clinical evidence of postpartum hemorrhage increased
with the severity of thrombocytopenia (►Fig. 2).
In multivariate models, women with thrombocytopenia
had increased odds of both clinical evidence of hemorrhage
(adjusted odds ratio [aOR]: 1.68, 95% confidence interval
[CI]: 1.52–1.83) and laboratory evidence of hemorrhage
(aOR: 1.60, 95% CI: 1.38–1.86) compared with women with-
out thrombocytopenia. When further classifying by the
severity of thrombocytopenia, odds of both clinical and
laboratory evidence of hemorrhage increased with
the degree of thrombocytopenia, considering those with
normal platelets as the reference group (►Table 3). Women
with platelets < 50,000/mL had ninefold odds of clinical
evidence of hemorrhage compared with women without
thrombocytopenia and over fourfold odds of laboratory
evidence of hemorrhage.
Fig. 1 Flow chart describing study population.
Table 1 Maternal demographic, clinical, and delivery characteristics by thrombocytopenia in the Maternal–Fetal Medicine Unit




Normal platelets (n ¼ 48,986)
n (%)
p-Value
Maternal age (SD) 29.2 (6.1) 28.5 (6.1) <0.001
Race/ethnicity
White 2,650 (47.2) 21,021 (42.9) <0.001
Black 1,523 (27.1) 14,774 (30.1)
Hispanic 1,153 (20.6) 10,879 (22.2)
Delivery BMI (kg/m2) (SD) 31.5 (5.2) 33.0 (7.2) <0.001
Preeclampsia, eclampsia, or HELLP syndrome 1,142 (20.4) 4,724 (9.6) <0.001
Tobacco use 624 (11.1) 7,332 (15.0) <0.001
Magnesium sulfate treatment 1,111 (19.8) 4,639 (9.5) <0.001
Nulliparous 1,442 (25.8) 11,122 (22.8) <0.001
Multiple gestation 3,548 (7.2) 757 (13.5) <0.001
Prior cesarean delivery 3,475 (62.2) 32,472 (66.5) <0.001
Mean gestational age at delivery (SD) 37.5 (3.6) 37.9 (3.4) <0.001
Delivery at < 37 wk 1,609 (28.7) 11,072 (22.6) <0.001
Delivery at < 32 wk 510 (9.1) 3,459 (7.2) <0.001
Labored 2,908 (51.8) 27,196 (55.5) <0.001
Cesarean delivery 4,680 (83.4) 39,928 (81.5) <0.001
General anesthesia 572 (10.5) 3,008 (6.3) <0.001
Abbreviations: BMI, body mass index; SD, standard deviation.
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Subgroup analyses were then performed to evaluate the
persistence of relationship between thrombocytopenia and
hemorrhage in the presence (n ¼ 5,866) and absence of
preeclampsia (n ¼ 48,731) in women delivering vaginally
(n ¼ 9,989) and by cesarean section (n ¼ 44,608). The
relationship between increasing risk of hemorrhage and
worsening severity of thrombocytopenia persisted in these
analyses (►Table 3).
Comment
We found that thrombocytopenia—regardless of severity—
conferred a significant increased risk of postpartum hemor-
rhage. Results were consistent regardless of whether we
used a clinical definition or an objective, laboratory-derived
definition. Additionally, we found that the risk of hemor-
rhage increased as the platelet count decreased with the
most dramatic odds occurring with platelets < 50,000/mL.
These findings persisted despite controlling for confounders.
The threshold at which the risk of hemorrhagic morbidity
increaseswith thrombocytopenia is not well established in the
obstetric literature. A small retrospective study previously
illustrated increased postpartum hemorrhage with platelets
< 40,000/mL in the setting of HELLP syndrome,17 but hemor-
rhage risk with milder thrombocytopenia remained unclear.
Another small retrospective study of patients with immune
thrombocytopenic purpura did not illustrate an increased risk
of hemorrhage with worsening thrombocytopenia.18 Notably,
both of these studies were small, and neither was adequately
powered to detect differences in hemorrhage risk of the
magnitude found in this study. Traditional teaching is that
thrombocytopeniashouldnot increasehemorrhage riskas long
as platelets are above 50,000/mL, and guidelines for manage-
mentofwomenwith immunethrombocytopenicpurpurastate
that a platelet count of  50,000/mL is adequate for cesarean
delivery.19 Thefindings of this study are therefore notable; our
analysis confirms that risk forhemorrhagicmorbidity isgreatly
increased inwomenwithplatelets < 50,000/mL, and that even
Table 2 Clinical and laboratory evidence of hemorrhage by presence of thrombocytopenia in the Maternal–Fetal Medicine Unit




Normal platelets (n ¼ 48,986)
n (%)
p-Value
Clinical evidence of hemorrhage 654 (11.7) 3,208 (6.6) <0.001
Medical treatment of atony 325 (5.8) 1,963 (4.0) <0.001
Blood transfusion 262 (4.7) 1,160 (2.4) <0.001
Coagulopathy 149 (2.7) 171 (0.4) <0.001
Repeat laparotomy 24 (0.4) 117 (0.2) 0.008
Peripartum hysterectomy 33 (0.6) 234 (0.5) 0.261
Intensive care unit admission 96 (1.7) 313 (0.64) <0.001
Laboratory evidence of hemorrhage 352(8.3) 1,624 (4.6) <0.001
Fig. 2 Percentage of patients with laboratory or clinical evidence of hemorrhage by antepartum platelet count.
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milder degrees of thrombocytopenia appear to be associated
with a clinically meaningful increased risk of peripartum
hemorrhage. Nonetheless, we emphasize that though the risk
of hemorrhage is elevated for women with platelet counts
< 150,000 mL, these data alone are insufficient to change
routine clinical practice. For example, we do not recommend
a routine platelet transfusion prior to delivery for womenwith
platelets < 150,000 on the basis of these results but would
recommend an increased clinical vigilance for postpartum
hemorrhage.
In this study, we examined two separate but complemen-
tary outcomes. We chose to examine laboratory evidence of
hemorrhage to identify women with clinically significant
decreases in hemoglobin that would be consistent with true
postpartum hemorrhage. Many women who meet the
criteria for postpartum hemorrhage may not experience a
decrease in hemoglobin as profound as a drop of 4 points or
receive blood transfusion prior to such a decrease andwould
not therefore show laboratory evidence of hemorrhage.
Further, a decrease in hemoglobin of 4 mg/dL may also be
attributed to a dilutional effect in some individuals, which
may have produced misclassification bias. As such, we also
chose to examine clinical evidence of hemorrhage as a
composite outcome of clinically meaningful outcomes asso-
ciatedwithmaternalmorbidity. There is also a small risk that
neither hemorrhage definition would capture a minority of
cases (e.g., postpartum hemorrhages that did not require
transfusion and were not secondary to uterine atony).
Our study has several strengths. The study population was
large and derived from multiple centers across the United
States, increasing heterogeneity and generalizability. Data
collection was prospective and uniform by trained research
staff. Our hemorrhagic outcomes were objective and did not
use estimated blood loss, a subjective measure with tradition-
ally very poor inter-rater reliabilityand equally poor sensitivity
forpostpartumhemorrhage.20–23 Inotherwords, theoutcomes
used in this study were measurable, reproducible and thus,
clinically meaningful.
Our study also has several limitations. Despite the large
population, relatively few patients had thrombocytopenia
< 100,000/mL. However, this likely represented the uncom-
mon distribution of severe thrombocytopenia in the obstetric
population. While we were able to compare the incidence of
hypertensive disorders of pregnancy between women with
and without thrombocytopenia, other common etiologies of
thrombocytopenia (e.g., gestational thrombocytopenia, im-
mune-mediated thrombocytopenia) were not documented.
Thus, we were unable to control for etiology of thrombocyto-
penia in this analysis. Additionally, we did not have informa-
tion regarding platelet trends; it is possible that acutely falling
platelets may confer higher risk compared with platelets that
are low, but stable. Finally, though baseline rates of hemor-
rhage in this cohort were similar to what we expected, the a
priori risk for hemorrhage was likely to be higher in this
population of women with a prior cesarean or planning to
undergo cesarean, limiting the ability to generalize these
results to women planning vaginal delivery without history
of prior cesarean. As described above, we are unable to
recommend antepartum or preoperative platelet transfusion
based on the findings of this study.
Existing data are sparse surrounding hemorrhage risk
associated with thrombocytopenia, particularly among
women with mild and moderate thrombocytopenia. Based
on our findings, clinicians should consider women with
any degree of thrombocytopenia to be at an increased risk
for peripartum hemorrhage during the antepartum risk
assessment, and should have a low threshold to initiate
hemorrhage management as clinically indicated. Thresholds
for platelet transfusion in the obstetric setting should be
addressed in future studies.
Condensation
The risk of postpartum hemorrhage is directly propor-
tional to the severity of thrombocytopenia.
Note
This study was presented, in part, as a poster at the 37th
Annual Pregnancy Meeting of the Society for Maternal–
FetalMedicine from January 22 to 28, 2017 at Las Vegas, NV
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